

<b>Info Sheet for Technical description</b>
---

No. XXXX (事務局付番)

**Organization**

\* Mandatoty fields

Name of Organization*	VCCT Inc.	
Address, City, States, Zip, Country*	Kobe Eye Center 5F, 2-1-8 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 Japan	
URL	<a href="https://www.vcct.jp/">https://www.vcct.jp/</a>	
Brief Descriptions of Organization* (Approx. 100 words)	<p>VCCT Inc. are dedicated to the development and practical application of advanced treatment methods focused on retinal outer layer diseases. One of our main missions is to conduct research on personalized treatment strategies tailored to each patient's condition.</p> <p>To achieve this, we have developed techniques to specifically induce and proliferate visual cells and retinal pigment epithelium (RPE) cells using iPS cells.</p> <p>In addition, we are conducting meticulous research on surgical techniques and postoperative care to maximize the effects of transplantation. We are working on clinical applications in close collaboration with Kobe City Eye Hospital.</p>	
Contact address	Name*	Kaoru Usuyama
	Department* / Position	PR
	E-mail* / TEL	<a href="mailto:info@vision-care.jp">info@vision-care.jp</a>

**What kind of technology do you want to offer? \***

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(\*) that are not included in the above (Group B) → Please see **Sheet [C]**
- \* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

**If you agree to the following, please check "Yes" below. \***

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

**Do you have any collaborations/partnerships with pharmaceutical companies?**

- Yes
- No

**If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?**

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

**Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \***

Options*	Comments
<input type="checkbox"/> Yes	Please contact us directly
<input checked="" type="checkbox"/> No	

Filled in by\*

Date\*

	Seiji HORI
	2023/10/3

**Sheet [A]** Clinical Development Pipelines**Info Sheet for Technical overview**

No. XXXX (事務局付番)

\* Mandatoty fields

**Title\*****Pipeline of VCCT****Development Phase\***

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> Basic Research                      | <input type="checkbox"/> Drug Discovery            | <input checked="" type="checkbox"/> Pre-Clinical    |
| <input checked="" type="checkbox"/> Clinical Trial (Phase I) | <input type="checkbox"/> Clinical Trial (Phase II) | <input type="checkbox"/> Clinical Trial (Phase III) |
| <input type="checkbox"/> Review                              | <input type="checkbox"/> Others                    |   |

**Disease Area\***

- |  |   |   |
|--|---|---|
| <input type="checkbox"/> Cancer          | <input type="checkbox"/> Central nervous system | <input checked="" type="checkbox"/> Ophthalmology |
| <input type="checkbox"/> Musculoskeletal | <input type="checkbox"/> Endocrine / Metabolism | <input type="checkbox"/> Cardiovascular           |
| <input type="checkbox"/> Urogenital      | <input type="checkbox"/> Digestive organ        | <input type="checkbox"/> Blood                    |
| <input type="checkbox"/> Infection       | <input type="checkbox"/> Dermatology            | <input type="checkbox"/> Immunity                 |
| <input type="checkbox"/> Otolaryngology  | <input type="checkbox"/> Respiratory            | <input type="checkbox"/> Others                   |

**Description\***

MastCT01 Allogeneic iPSC-derived RPE

Targets: Retinal degeneration diseases with RPE degeneration

MastCT03 Allogeneic Genome-edited iPS cell-derived RPE cells

Targets: Retinal degeneration diseases with RPE degeneration

MastCT03 is Genome-edited iPS cell-derived RPE cells genetically engineered to lack HLA molecules. MastCT03 targets various retinal degenerative diseases associated with retinal pigment epithelial degeneration, and although it is an allogeneic cell, it has improved safety by decreasing the risk of immune rejection after transplantation .

MastCT-PR Allogeneic iPS cell-derived retinal organoids

Targets: Retinitis Pigmentosa, AMD and others

MastCT-PR differentiates retinal organoids from allogeneic iPS cells. A rectangle-shaped retinal tissue excised from the organoids and transplanted under the patient's retina. To date, similar technology has been used in clinical research at Kobe City Eye Hospital.

<https://www.vcct.jp/en/pipeline-en/>

**Filled in by\***

Seiji HORI

**Date\***

2023/10/3